← Back

Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel allosteric ion channel modulators for central nervous system disorders. Its lead candidate BNC210, a selective negative allosteric modulator of the α7 receptor, is in development for social anxiety disorder and in Phase 2b for post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody targeting cancer stem cells that has completed Phase 1, and BNC105 for cancer. Additional programs include NextGen in preclinical development for multiple CNS indications and a Kv3.1/3.2 agonist in preclinical development for cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. It collaborates with Merck & Co., Inc. on α7 receptor positive allosteric modulators for cognitive dysfunction associated with Alzheimer's disease and other CNS conditions. Formerly Bionomics Limited, it changed its name to Neuphoria Therapeutics Inc. in December 2024, was incorporated in 1996, and is based in Burlington, Massachusetts.

Price · split & dividend adjusted
News & notes moving NEUP
NEUP▼

Halper Sadeh LLC Investigates Whether SAFT, NEUP, RMAX, NRIM Are Obtaining Fair Deals for Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws or breaches of fiduciary duties to shareholders. The investigations concern Safety Insurance Group Inc.'s sale to an affiliate of Mapfre S.A. for $105.00 per share in cash, Neuphoria Therapeutics Inc.'s merger with Scancell Holdings plc where Neuphoria shareholders would own 14.5% of the combined company, RE/MAX Holdings Inc.'s sale to The Real Brokerage Inc. for either 5.152 shares of the combined company or $13.80 in cash per share, and Northrim BanCorp Inc.'s merger with PBCO Financial Corporation. The firm notes that insiders may receive substantial financial benefits not available to ordinary shareholders and that the proposed transactions may contain terms limiting superior competing offers. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.
NEUP ▼NRIM ▼RMAX ▼SAFT ▼0NQ2.LSE SCLP.LSE
NEUP · Capital · Negative Merger with Scancell where Neuphoria shareholders get only 14.5% of combined company, potentially unfair.
NRIM · Capital · Negative Merger with PBCO Financial Corporation under investigation for unfair terms.
RMAX · Capital · Negative Sale to The Real Brokerage Inc. under investigation for potentially unfair deal terms.
SAFT · Capital · Negative Sale to Mapfre S.A. under investigation for potential securities law violations.
0NQ2.LSE · Capital · Neutral Mapfre is the acquirer of Safety Insurance; investigation may affect deal but not directly negative for Mapfre.
SCLP.LSE · Capital · Neutral Scancell is merging with Neuphoria; the investigation may affect deal terms but Scancell is not the target.
Read original ↗
GlobeNewswire·66dRead more →
NEUP

Monteverde Law Firm Investigates Mergers of Northrim Bancorp, Neuphoria Therapeutics, Safety Insurance, and RE/MAX

Class action attorney Juan Monteverde of Monteverde & Associates PC announced investigations into four proposed mergers. The firm is examining Northrim Bancorp's merger with PBCO Financial Corporation, Neuphoria Therapeutics' merger with Scancell Holdings where Neuphoria stockholders would own 11.1% of the combined company, Safety Insurance Group's sale to a Mapfre affiliate at $105.00 per share in cash, and RE/MAX Holdings' sale to The Real Brokerage where shareholders may receive 5.152 shares of the combined company or $13.80 in cash per share. The RE/MAX shareholder vote is scheduled for August 14, 2026. Monteverde & Associates PC, a national class action securities firm headquartered at the Empire State Building, has recovered millions of dollars for shareholders and was recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
NEUP NRIM RMAX SAFT SCLP.LSE
NEUP · Capital · Neutral Merger investigation announced; outcome uncertain for Neuphoria Therapeutics.
NRIM · Capital · Neutral Merger investigation announced; outcome uncertain for Northrim BanCorp.
RMAX · Capital · Neutral Merger investigation announced; outcome uncertain for RE/MAX Holdings.
SAFT · Capital · Neutral Merger investigation announced; outcome uncertain for Safety Insurance Group.
SCLP.LSE · Capital · Neutral Scancell Holdings is merging with Neuphoria Therapeutics; the investigation is about the merger terms, but no clear positive or negative impact on Scancell is stated.
PBCO Financial Corporation · Capital · Neutral PBCO Financial Corporation is merging with Northrim Bancorp; the investigation is about the merger terms, but no clear positive or negative impact on PBCO is stated.
Read original ↗
GlobeNewswire·66dRead more →
NEUP▲

Neuphoria confirms talks with Scancell about potential acquisition

Neuphoria Therapeutics confirmed it is in discussions with London-listed Scancell Holdings about a potential acquisition of Neuphoria by Scancell, with Scancell becoming a Nasdaq-listed company after any deal. The statement follows an earlier announcement by Scancell about a possible combination, made after UK press speculation and in compliance with UK regulations. Neuphoria cautioned that there is no certainty an agreement will be reached, nor on the terms or whether a transaction will proceed. Any further announcements will be made in line with SEC and Nasdaq rules.
NEUP ▲SCLP.LSE ▲
NEUP · Capital · Positive Potential acquisition by Scancell, which would result in Nasdaq listing, is a positive capital event for Neuphoria.
SCLP.LSE · Capital · Positive Scancell is in talks to acquire Neuphoria and become Nasdaq-listed, a positive M&A and listing development.
Read original ↗
GlobeNewswire·100dRead more →
© 2026 MarketDXAsset